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L I V E R  F I B R O S I S
Hyaluronan synthase 2–mediated hyaluronan production 
mediates Notch1 activation and liver fibrosis
Yoon Mee Yang1,2, Mazen Noureddin1,3*, Cheng Liu4*, Koichiro Ohashi1, So Yeon Kim1, 
Divya Ramnath5, Elizabeth E. Powell6,7, Matthew J. Sweet5, Yoon Seok Roh1,8, I-Fang Hsin1, 
Nan Deng9, Zhenqiu Liu9, Jiurong Liang1,10,11, Edward Mena12, Daniel Shouhed13, Robert F. Schwabe14, 
Dianhua Jiang1,10,11, Shelly C. Lu1, Paul W. Noble1,10, Ekihiro Seki1,11†
Hyaluronan (HA), a major extracellular matrix glycosaminoglycan, is a biomarker for cirrhosis. However, little is 
known about the regulatory and downstream mechanisms of HA overproduction in liver fibrosis. Hepatic HA and 
HA synthase 2 (HAS2) expression was elevated in both human and murine liver fibrosis. HA production and liver 
fibrosis were reduced in mice lacking HAS2 in hepatic stellate cells (HSCs), whereas mice overexpressing HAS2 
had exacerbated liver fibrosis. HAS2 was transcriptionally up-regulated by transforming growth factor–b through 
Wilms tumor 1 to promote fibrogenic, proliferative, and invasive properties of HSCs via CD44, Toll-like receptor 4 
(TLR4), and newly identified downstream effector Notch1. Inhibition of HA synthesis by 4-methylumbelliferone 
reduced HSC activation and liver fibrosis in mice. Our study provides evidence that HAS2 actively synthesizes HA 
in HSCs and that it promotes HSC activation and liver fibrosis through Notch1. Targeted HA inhibition may have 
potential to be an effective therapy for liver fibrosis.
INTRODUCTION
Liver fibrosis is a consequence of chronic liver diseases, including 
chronic hepatitis B and C viral infections, and alcoholic and non-
alcoholic steatohepatitis (NASH) (1, 2). Cirrhosis, the end stage of liver 
fibrosis, is the 12th leading cause of death in the United States, and 
about 32,000 people die annually (3). Although two antifibrotic 
agents have been approved for treating idiopathic pulmonary fi-
brosis (4), currently there are no Food and Drug Administration– 
approved antifibrotics for cirrhosis. The curative therapy for cirrhosis 
remains liver transplantation unless the underlying disease can be 
successfully treated. Furthermore, coincident with increased obesity, 
the prevalence of NASH is rapidly rising (5). To date, NASH-mediated 
fibrosis has become the second leading cause of liver transplantation 
(6). The unmet medical needs for liver fibrosis, particularly as mediated 
by NASH, are remarkable.
The production and deposition of extracellular matrix (ECM) com-
ponents, such as collagen, that replace functional liver tissues feature 
prominently in liver fibrosis (1, 2). Hyaluronan (HA), another major 
ECM component, consists of repeating disaccharides D-glucuronic 
acid and N-acetyl-D-glucosamine. HA is synthesized as high–molecular 
weight (HMW) forms (MW, >1000 kDa) through HA synthase 1 
(HAS1), HAS2, and HAS3 (7). During tissue injury and inflammation, 
HMW-HA is degraded into lower–molecular weight (LMW; MW, 
~100 to 300 kDa) species through hyaluronidases or nonenzymatically 
by reactive oxygen species (7). Accumulated LMW-HA induces tissue 
injury and inflammation through the HA receptors CD44 and Toll-like 
receptor 4 (TLR4) (7, 8). LMW-HA is further degraded into HA 
oligomers (<100 kDa) and then eliminated from the body.
HA accumulates in the ECM in the context of tissue remodeling and 
drives inflammation, fibrosis, and cancer development through acti-
vation of TLR4 and CD44 (7, 8). The mechanistic roles of TLR4 and CD44 
have been reported in lung injury and fibrosis (7–9). HA-TLR4 in-
teraction mediates chemokine production in lung macrophages and 
initiates a regenerative response in type 2 alveolar epithelial cells 
(AEC2) after injury (8, 10). CD44 promotes an HA-mediated invasive 
phenotype in lung fibroblasts and ECM production in lung fibrosis 
(9). In the liver, TLR4 activates hepatic stellate cells (HSCs), which 
then promote liver fibrosis. Gut-derived lipopolysaccharide (LPS) 
has been identified as a TLR4 ligand involved in the progression of 
liver fibrosis (11). CD44 is required for macrophage and liver sinus-
oidal endothelial cell (LSEC) clearance of HA from sites of inflam-
mation (12, 13). However, the role of HA-mediated TLR4 and CD44 
signaling in HSCs in the development of liver fibrosis is unknown.
Notch signaling is involved in cellular processes including myo-
fibroblast differentiation and promotes lung, kidney, and skin fi-
brosis (14). In the liver, Notch1 is overexpressed in patients with 
hepatitis B or C infections and hepatocellular carcinoma (15). 
Jagged-1, a Notch ligand, is up-regulated in biliary fibrosis and non-
alcoholic fatty liver disease (NAFLD) (16, 17). Previous studies 
using nonselective Notch inhibitors have suggested that Notch 
signaling plays a role in HSC activation and liver fibrosis (18, 19). 
However, the role of Notch1 in HSC activation and liver fibrosis, 
and the relationship between HA and Notch1 in HSCs, has not been 
explored.
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In healthy participants, serum HA concentrations are low because 
they are exquisitely fine-tuned through the rapid clearance by LSECs. 
In cirrhosis, dysfunctional LSECs reduce the uptake of HA because of 
the decreased expression of CD44, and HA accumulates in the blood 
(12, 13). Measurement of blood HA concentration has been used as a 
noninvasive biomarker for cirrhosis (20). Here, we provide evidence 
that HA overproduction through dysregulated HAS2 expression 
contributes to the development of liver fibrosis. We show that HAS2 
is transcriptionally regulated by Wilms tumor 1 (WT1) in HSCs and 
that HA promotes fibrogenic, proliferative, and invasive phenotypes 
of HSCs through activation of CD44 and TLR4 in an autocrine man-
ner. We found that Notch1 contributes to HA-mediated HSC activa-
tion and fibrosis, and we demonstrated that inhibiting HA synthesis 
has potential for the treatment of liver fibrosis.
RESULTS
HAS2 and HA are overexpressed in human and  
murine liver fibrosis
To determine the roles of HA synthases in human liver fibrosis, we 
examined liver specimens from three different etiologies: hepatitis B–, 
hepatitis C–, and NASH-induced liver fibrosis. In both hepatitis B– 
and hepatitis C–induced liver fibrosis, we observed increased hepatic 
expression of HAS2 in advanced fibrosis (F4) compared to earlier 
stages (Fig. 1A and fig. S1A). In contrast, the hepatic expression of 
HAS1 and HAS3 was unchanged between advanced and early fibrosis 
(fig. S1, A and B). The analysis of Gene Expression Omnibus database 
(GSE84044) for hepatitis B–induced fibrosis corroborated our results 
(fig. S1C). HAS2 protein expression was also elevated in fibrotic 
patient livers, as compared to those from patients with early-stage 
disease (Fig. 1B). HAS2 was expressed in activated HSCs, as identified 
by increased a–smooth muscle actin (a-SMA) expression (Fig. 1C). 
Furthermore, serum HA correlated with hepatic HAS2 mRNA 
(Fig. 1D) but not with HAS1 or HAS3 (fig. S1D). NASH is the most 
common etiology of liver fibrosis in recent years. Similar to our 
observations in viral hepatitis-induced fibrosis, NASH-induced 
fibrosis showed increased HA accumulation and HAS2 expression 
in the liver (Fig. 1, E to G).
To explore the role of HAS2 in liver fibrosis, we examined 
the expression of the HAS2 product HA in mouse liver fibrosis 
models, including cholestasis-induced [bile duct ligation (BDL) or 
3,5-diethylcarbonyl-1,4-dihydrocollidine (DDC) diet], NASH-induced 
[choline-deficient high-fat diet (CDHFD) or choline-deficient amino 
acid–defined (CDAA) diet], and toxin-induced [carbon tetrachloride 
(CCl4) or thioacetamide (TAA)] fibrosis models. HA was present in 
nonparenchymal cells in fibrotic livers (Fig. 2A). We costained for 
HA and cell-specific markers in BDL-induced fibrotic livers and 
found that HA was mainly expressed in Desmin+ HSCs but not in 
HNF4a+ hepatocytes, F4/80+ Kupffer cells, or CD31+ LSECs (Fig. 2B 
and fig. S2A). Next, we assessed HAS expression in the liver. Has1 
and Has2 expression was up-regulated in the fibrotic liver, whereas 
Has3 was not (Fig. 2C). The up-regulation of Has2 was much greater 
than that of Has1 (Fig. 2C). We then examined the expression of 
Has2 in HSCs, Kupffer cells, and hepatocytes from fibrotic livers. 
Has2 expression was up-regulated in in vivo–activated HSCs from 
BDL mice, whereas it was not up-regulated in Kupffer cells and 
hepatocytes after BDL (Fig. 2D). We further compared Has2 mRNA 
expression among hepatocytes, Kupffer cells, HSCs, and LSECs. Has2 
expression was low in all cell populations examined, except for activated 
HSCs (Fig. 2E). Activated HSCs showed high expression of Has2, 
which was 20-fold higher than in Kupffer cells (Fig. 2E). In contrast, 
Has1 and Has3 mRNA expression was lower in activated HSCs than 
in quiescent HSCs (fig. S2B). Our results suggest that HAS2 is the 
critical HA synthase in HSC activation and liver fibrosis.
HSC-derived HAS2 is the critical enzyme for HA production 
and liver fibrosis in mice
To investigate the role of HAS2 in liver fibrosis, we performed a 
gain-of-function study using ASMA-HAS2 transgenic (Tg) mice (9). 
These mice overexpress HAS2 in a-SMA–expressing cells (including 
HSCs) under control of the Acta2 promoter. Mice were subjected to 
BDL- or CCl4-induced liver fibrosis, which increased the liver HA 
content in ASMA-HAS2 Tg mice (Fig. 3, A, B, D, and E). ASMA-HAS2 
Tg mice showed augmented collagen deposition along with increased 
HSC activation, as shown by Sirius red staining, a-SMA staining, and 
Acta2 and Timp1 mRNA expression (Fig. 3, A, C, D, and F, and fig. S3). 
These findings demonstrate that overproduction of HA by overexpressing 
HAS2 in liver myofibroblasts promotes HSC activation and liver fibrosis.
HSCs are the primary cells that constitute the myofibroblast pool 
in liver fibrosis (21). To characterize the role of HSC-derived HAS2 
in liver fibrosis, we generated HSC-specific Has2 knockout (Has2DHSC) 
mice, in which specific deletion of Has2 in HSCs was confirmed 
(fig. S4). These mice were subjected to BDL and DDC diet–induced 
liver fibrosis models. In parallel with HA content, liver fibrosis 
induced by BDL and DDC diet in wild-type (WT) mice was dimin-
ished in Has2DHSC mice (Fig. 3, G to I, and fig. S5, A to C). These 
findings demonstrate that HAS2 expressed in HSCs plays a crucial 
role in hepatic HA production and liver fibrosis.
NASH-induced liver fibrosis was developed by CDHFD feeding, 
which closely recapitulates the liver pathology of human NASH (22). 
CDHFD feeding increased the hepatic HA content and liver fibrosis 
in WT mice, but these increases were reduced in Has2DHSC mice 
(Fig. 3, J to L). These results indicate that HSC-produced HAS2 
plays a major role in NASH-mediated fibrosis. Has2 deletion in 
HSCs did not affect CDHFD-induced weight gain, hepatic lipid 
accumulation, or glucose intolerance (fig. S6).
HAS2 regulates profibrogenic phenotypes of HSCs
Using HSCs with Has2 ablation and HAS2 overexpression, we 
performed RNA sequencing (RNA-seq) to examine the expression of 
genes encoding ECM proteins and ECM-associated pathways. ECM- 
encoded genes and integrins were up-regulated in HAS2-overexpressing 
HSCs compared to Has2-deleted HSCs (Fig. 4A). The RNA-seq data 
were then validated by qPCR. Compared to WT HSCs, the mRNA 
expression of Itga1, Fn1, Col4a1, Col1a1, and Acta2 was reduced in 
Has2-ablated HSCs but increased in HAS2-overexpressing HSCs 
(Fig. 4B). Proliferative and invasive capacities of HSCs were reduced 
by Has2 deletion but enhanced by HAS2 overexpression (Fig. 4, C and D). 
These results suggest that HAS2 regulates HSC functions including 
ECM production, proliferation, and invasion, likely via autocrine 
production of HA.
LMW-HA mediates proinflammatory and profibrogenic HSC 
functions through CD44 and TLR4
HA production and degradation is a dynamic process. HA generated 
as HMW forms can be degraded into LMW-HA in the presence of 
inflammation (7). We detected total and HMW forms of HA in sera 
of individuals without fibrosis, whereas LMW-HA (100 to 300 kDa) 
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Fig. 1. Expression of HAS2 and HA is increased in human liver fibrosis. (A) Hepatic HAS2 mRNA expression in patients with fibrosis and chronic hepatitis B virus (HBV). 
(B) Representative immunohistochemical (IHC) staining images of HAS2 in liver sections of patients with HBV with F0/1 or F4 stages. Boxed regions are shown at higher 
magnification in the bottom row. Scale bar, 100 mm. (C) Colocalization of a-SMA and HAS2 in the liver of patients with HBV. Representative immunofluorescence staining 
images are shown (F0/1, n = 10; F4, n = 10). Boxed regions are shown at higher magnification. Blue, 4′,6-diamidino-2-phenylindole (DAPI). Scale bars, 100 mm. (D) Pearson 
correlation coefficient analysis of HAS2 mRNA expression and serum HA concentration of patients with HBV. (E and F) Representative images and quantification of HA 
staining in liver sections of patients with NASH-mediated liver fibrosis. HABP, HA-binding protein. Scale bar, 100 mm. (G) Hepatic HAS2 mRNA expression in patients with 
NAFLD. F0, no fibrosis; F1 to F4, fibrosis. In (A), (F), and (G), data are means ± SD. One-way analysis of variance (ANOVA) with Tukey’s post hoc analysis (A and F) and 
two-tailed Student’s t test (G). *P < 0.05 and **P < 0.01.
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Fig. 2. HAS2 and HA are overexpressed in murine liver fibrosis. (A) Representative images of HA staining in mouse liver fibrosis. ND, normal diet; CSAA, choline-sufficient 
amino acid–defined. Scale bar, 100 mm. (B) Representative double immunofluorescence staining images of desmin and HA. Boxed regions are shown at higher magnification. 
(C) Hepatic Has mRNA expression in mouse liver fibrosis (sham, n = 10 or BDL, n = 12; ND, n = 5 or DDC, n = 9; ND, n = 5 or CDHFD diet, n = 7; corn oil, n = 5 or CCl4, n = 8). 
Mice underwent BDL for 3 weeks. *P < 0.05 and **P < 0.01 versus relative control. (D) Quantitative reverse transcription polymerase chain reaction (qRT-PCR) for Has2 
mRNA in primary HSCs, Kupffer cells (KC), and hepatocytes (HEP) isolated from sham- or BDL-operated mice 5 days after surgery (n = 3 per group). **P < 0.01; N.S., not 
significant. (E) qRT-PCR assays for Has2 mRNA in mouse liver cells (n = 3 per group). Activated HSC: 7-day culture-activated HSC. **P < 0.01. Data are means ± SEM. Two-tailed 
Student’s t test (C and D) and one-way ANOVA with Tukey’s post hoc analysis (E).
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Fig. 3. HSC-derived HAS2 promotes liver fibrosis. (A) Representative images of HA and Sirius red staining of sections of mouse liver. Mice underwent BDL for 2 weeks 
(Sham-WT, n = 5; Sham-Tg, n = 3; BDL-WT, n = 10; BDL-Tg, n = 7). (B) Liver HA content by enzyme-linked immunosorbent assay (ELISA). (C) Sirius red–positive area (collagen) 
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forms were negligible (Fig. 5A). During the progression of liver 
fibrosis, total HA concentration increased (Fig. 5A), and LMW forms 
of HA were increased in sera from patients with fibrosis as compared 
to individuals without fibrosis (Fig. 5A). In mouse fibrotic livers, the 
100- to 300-kDa LMW-HA was the dominant form of HA (Fig. 5B). 
To examine the effect of size of HA, HSCs were treated with LMW- and 
HMW-HA. The treatment of HSCs with LMW-HA increased Timp1, 
Ccl2, and Cxcl1 mRNA expression, whereas HMW-HA treatment did 
not (Fig. 5C). Although continuously exposing HSCs to endogenous, 
HAS2 overexpression–produced HA enhanced ECM production 
(Fig. 4, A and B), Col1a1 and Acta2 mRNA expression was not 
up-regulated by a short LMW-HA treatment (Fig. 5C). Conversely, 
HMW-HA suppressed expression (Fig. 5C). Similarly, the treatment 
of Kupffer cells with LMW-HA up-regulated Ccl2 and Cxcl1, whereas 
HMW-HA had no effect (Fig. 5D). Our results suggest that LMW-HA, but 
not HMW forms, generated in injured tissues augments inflammatory 
and fibrogenic responses in HSCs and Kupffer cells.
TLR4 and CD44 are major HA receptors (8). We previously 
reported that TLR4 expressed in HSCs promotes liver fibrosis (11). 
In normal liver, CD44 is weakly expressed by lymphocytes and 
Kupffer cells but not hepatocytes (13). Fibrotic insults by BDL or CCl4 
increased the CD44 expression, especially in collagen-producing 
cells. CD44 expression was further augmented in mice with HAS2 
overexpression (Fig. 5E). Cd44 and Tlr4 mRNA expression was 
increased in HSCs from BDL mice compared to controls (fig. S7), 
underscoring that fibrotic HSCs up-regulate CD44 and TLR4 
expression. To dissect the role of CD44 and TLR4 in HSCs, we used 
RNA-seq analysis on WT, Cd44−/−, and Tlr4−/− HSCs after in vitro 
culturing in which HSCs should be affected by endogenously produced 
HA (fig. S7). Col1a1, Itga2, and Itga5 were predominantly regulated 
by CD44, whereas Sdc4 and Thbs1 were TLR4 dominant. In contrast, 
Tnc, Col4a5, Itgb5, and Hmmr were regulated by both TLR4 and CD44 
(Fig. 5F). Both CD44 and TLR4 regulated LMW-HA–induced Timp1 
and Ccl2 expression (Fig. 5G). We also found that WT HSCs treated 
with HA-enriched conditioned medium showed enhanced HSC 
proliferation and invasion, whereas Cd44−/− or Tlr4−/− HSCs did not 
(Fig. 5, H and I, and fig. S8). Furthermore, HA-enriched conditioned 
medium also enhanced Kupffer cell migration, which was abolished 
by Cd44 or Tlr4 deficiency (Fig. 5J). These results suggest that the 
biological effects of HA on HSCs and Kupffer cells are mediated 
through CD44 and TLR4.
HAS2 mediates HSC activation and liver fibrosis  
through Notch1
To seek downstream effectors of HAS2, we analyzed the RNA-seq 
data of HAS2 Tg versus Has2DHSC HSCs and WT versus Cd44−/− or 
Tlr4−/− HSCs. We found that Notch-associated genes were regulated 
by HAS2, CD44, and TLR4 (Fig. 6, A and B). HSCs are the primary 
cells expressing Notch1 and its target Hes1 (fig. S9A). Hes1 expression 
was up-regulated in activated HSCs (fig. S9A), suggesting that 
Notch signaling is activated during HSC activation. Consistent with 
the RNA-seq results, liver tissue and HSCs from Has2DHSC and Cd44−/− 
mice had reduced expression of Notch1 and Hes1 (Fig. 6, C and D, 
and fig. S9B). These findings prompted us to examine whether 
HAS2-mediated HA promotes HSC activation and liver fibrosis 
through Notch1. Has2 and CD44 overexpression increased NOTCH1 
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mRNA expression (Fig. 6, E and F), suggesting the transcriptional 
regulation of NOTCH1 by HA-CD44. To elucidate the underlying 
mechanism of HA-CD44–mediated transcriptional regulation of 
NOTCH1, we searched for the putative CD44 intracellular domain 
(ICD) response element (CIRE) “CCTGCG” on the NOTCH1 
promoter/enhancer region. We found two putative CIREs located in 
the proximal NOTCH1 promoter region (CIRE1) and intron 1 (CIRE2). 
Chromatin immunoprecipitation (ChIP) analysis revealed that CD44 
interacted with the CIRE2 (Fig. 6G). CD44 overexpression increased 
NOTCH1 promoter/enhancer activity with the WT full-length reporter 
construct, whereas the reporter constructs with mutated CIRE2 
or lacking both exon 1 and intron 1 abrogated the ability of CD44 
to increase NOTCH1 promoter/enhancer activity (Fig. 6H). Together, 
HA-CD44 signaling transcriptionally regulates Notch1 in HSCs.
To investigate the role of Notch1 in liver fibrosis, we generated 
mice lacking Notch1 in HSCs (Notch1DHSC). LMW-HA–induced 
Fig. 5. CD44 and TLR4 me-
diate HA-induced HSC pro-
fibrogenic phenotypic 
change. (A) Total and frac-
tionated serum HA content 
in patients with fibrosis and 
NAFLD (F0/1, F2, and F3, n = 5 
per group; F4, n = 9). *P < 0.05 
and **P < 0.01 versus F0/1; 
#P < 0.05 versus F2; dP < 0.05 
versus F3. (B) Fractionated 
HA content in murine liver 
(sham-operated, n = 7; BDL- 
operated, n = 10). (C) Profibro-
genic and proinflammatory 
gene expression in mouse HSCs 
and (D) in mouse Kupffer cells 
(n = 3 to 5 per group). Cells were 
treated with vehicle (Con), 
LMW-HA, or HMW-HA. *P < 0.05 
and **P < 0.01 versus Con. 
(E) Representative images of 
immunofluorescence staining 
of sections of mouse liver. Blue, 
DAPI. Scale bar, 100 mm. (F) A 
heat map of genes related to 
ECM-receptor interaction. Each 
lane repre sents pooled WT, 
Cd44−/−, or Tlr4−/− HSCs from 
three mice. (G) qRT-PCR assay 
(n = 3 per group). Mouse HSCs 
were treated with or without 
LMW-HA for 12 hours. (H) BrdU 
incorporation assay. HSCs were 
treated with conditioned me-
dium (CM, days 4 to 7) (n = 6 
per group). (I) Matrigel inva-
sion assay (n = 4 per group). 
W T ,  C d 4 4− /− ,  o r  Tlr4−/− 
HSCs were plated onto the 
upper chamber, and condi-
tioned medium was placed in 
the lower chamber. (J) Mi-
gration of WT, Cd44−/−, or 
Tlr4−/− Kupffer cells toward 
HSC-conditioned medium 
(n = 3 to 6 per group). In (G) to 
(J), **P < 0.01 versus vehicle (or 
WT CM)–treated WT; #P < 0.05 
and ##P < 0.01 versus LMW-HA 
(or HAS2 Tg CM)–treated WT. 
Data are means ± SEM. One-
way ANOVA with Tukey’s post 
hoc analysis.
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Timp1 and Ccl2 mRNA up-regulation was reduced in Notch1-ablated 
HSCs, whereas LPS-induced expression was unaffected (Fig. 6I). 
HSC proliferation and invasion induced by HA-enriched conditioned 
media from HAS2 Tg HSCs were also abolished by Notch1 ablation 
(Fig. 6, J and K), demonstrating that Notch1 is required for HA-mediated 
profibrogenic phenotypes of HSCs. Notch1-ablated HSCs showed 
decreased Notch1 expression, along with reduced Timp1 and Acta2 
mRNA expression (Fig. 6L). Hepatic Notch1 and Hes1 expression 
was increased in BDL-induced liver fibrosis in WT mice (fig. S9C). 
Moreover, Notch1DHSC mice had reduced liver fibrosis compared with 
WT mice (Fig. 6M). In ASMA-HAS2 Tg mice that show increased 
liver fibrosis, additional deletion of HSC Notch1 reduced liver fibrosis, 
of which the fibrosis degree was similar to mice with single Notch1 
deletion (Fig. 6N), demonstrating the causal link of HAS2, Notch1 
signaling, and liver fibrosis. In addition, NOTCH1 expression was 
up-regulated in human fibrotic livers and strongly correlated with 
Fig. 6. Notch1, as a downstream mol-
ecule of HAS2-HA-CD44 signaling, 
promotes liver fibrosis. (A and B) Heat 
maps of genes related to Notch pathway. 
(A) RNA-seq for HSCs from Has2DHSC 
or HAS2 Tg mice. (B) RNA-seq for 
HSCs from WT, Cd44−/−, or Tlr4−/− mice. 
(C to F) Effect of Has2 or CD44 modu-
lation on Notch1. (C) Liver (n = 8 per 
group), (C and D) HSCs (n = 3 to 4 per 
group), and (E and F) human HSC line 
LX-2 (n = 5 to 6). (G) ChIP assay (n = 4). 
IgG, immunoglobulin G. (H) NOTCH1 
promoter activity in human embryonic 
kidney 293 A (HEK293A) (three replicates 
in each of four experiments). **P < 0.01 
versus −1239/+1684 (WT) and mock- 
transfected; ##P < 0.01 versus −1239/+1684 
(WT) and CD44-transfected. (I) qRT-PCR 
for Timp1 and Ccl2 (n = 3). Mouse HSCs 
were treated with vehicle (Con), LMW-
HA, or LPS for 12 hours. **P < 0.01 versus 
WT-Con; ##P < 0.01 versus WT-LMW; N.S. 
versus WT-LPS. (J) BrdU incorporation 
assay (n = 9). (K) Matrigel invasion assay 
(n = 3). (L) Effect of Notch1 depletion 
on expression of fibrogenic mRNAs in 
HSCs (n = 3). (M) Sirius red staining and 
quantification of collagen deposition 
in liver sections from mice with HSC- 
specific Notch1 deletion 3 weeks after 
BDL (sham-operated, n = 3 per group; 
BDL-operated, n = 7 per group). Scale bar, 
100 mm. (N) Sirius red staining in liver 
sections 2 weeks after BDL (WT, n = 10; 
Notch1DHSC, n = 9; ASMA-HAS2 Tg, n = 6; 
ASMA-HAS2 Tg/Notch1DHSC, n = 7). (C to N) 
Data are means ± SEM. (O) qRT-PCR 
(means ± SD) and (P) Pearson correlation 
coefficient analysis in liver tissue from 
patients with fibrosis and chronic 
hepatitis B. Two-tailed Student’s t test 
(C to F and L) and one-way ANOVA 
with Tukey’s post hoc analysis (G to 
K and M to O). *P < 0.05 and **P < 0.01.
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HAS2 expression (Fig. 6, O and P). These results suggest that Notch1, 
as a downstream effector of the HAS2-HA-CD44 signaling, contributes 
to the development of liver fibrosis. Furthermore, the Notch1 ligand 
Jagged-1 was highly expressed in Kupffer cells and HSCs in comparison 
to hepatocytes (fig. S10). This further suggests that Kupffer cell– and/or 
HSC-derived Jagged-1 may engage Notch1 in HSCs through juxtacrine 
interaction because of their close proximity, thereby activating 
profibrogenic Notch1 signaling.
HAS2 expression is transcriptionally regulated by  
WT1 in HSCs
Next, we investigated the transcriptional regulation of HAS2 expression 
in HSCs. Although transforming growth factor–b (TGF-b) up-regulated 
Has2 mRNA expression in HSCs (Fig. 7A), the HAS2 promoter 
region does not have putative SMAD-binding sequences; rather, it 
contains three putative WT1-binding sequences (Fig. 7B) identified 
through the PROMO analysis program (http://alggen.lsi.upc.es/cgi-bin/
promo_v3/promo/promoinit.cgi?dirDB=TF_8.3). WT1 overexpression 
increased Has2 promoter activity and mRNA (Fig. 7, B and C). The 
site-directed mutagenesis analysis of WT1-binding sites in the Has2 
promoter revealed that all three WT1-binding sites are required for 
the Has2 promoter activation (Fig. 7B). Because TGF-b treatment 
up-regulated Has2 and Wt1 expression (Fig. 7, A and D), we inves-
tigated the contribution of WT1 to TGF-b–mediated Has2 expression 
and fibrogenic responses. Silencing Wt1 diminished TGF-b–induced 
Has2 and Col1a1 up-regulation (Fig. 7, E and F). We then examined 
the contribution of HAS2-CD44-Notch1 to TGF-b–mediated fibrogenic 
response. Deficiency of Has2, Cd44, or Notch1 decreased TGF-b–
induced Col1a1 mRNA expression (Fig. 7G). These results suggest 
that the WT1-HAS2-HA-Notch1 pathway is a key contributor to 
TGF-b–induced profibrogenic activity. In addition to TGF-b treatment, 
in vitro culture and in vivo–activated HSCs showed up-regulated Wt1 
mRNA expression (Fig. 7, H and I). Hepatic WT1 expression was also 
up-regulated in fibrotic mouse livers and human cirrhosis (Fig. 7, I and J). 
There is a positive correlation between WT1 and HAS2 expression 
in human liver fibrosis (Fig. 7K). Our results demonstrate that WT1 
is an upstream regulator of HAS2 induction in HSCs.
Pharmacological inhibition of HA synthesis suppresses liver 
fibrosis progression
Last, we investigated whether inhibiting HA production could 
suppress the development of liver fibrosis using the HA synthesis 
inhibitor 4-methylumbelliferone (4-MU). 4-MU, also known as 
hymecromone, is an approved drug in Europe and Asia for treating 
biliary spasm and a dietary supplement for improving liver function 
(23). We used HSCs isolated from Col1a1 promoter-driven green 
fluorescent protein (GFP) Tg mice, in which cells express GFP upon 
increased Col1a1 promoter activity. 4-MU treatment reduced Col1a1 
promoter activity and mRNA expression in HSCs (Fig. 8, A to C). 
To examine the therapeutic potential of 4-MU on liver fibrosis, 
4-MU or vehicle was given orally daily to mice with BDL. The treatment 
of 4-MU began 1 week after BDL surgery and continued until the 
end of the experiments. Serum alanine aminotransferase concentration 
was similar between vehicle and 4-MU treatment groups, suggesting 
no remarkable hepatotoxicity by 4-MU (fig. S11A). 4-MU treatment 
suppressed liver HA content, Notch1 mRNA expression, HSC activation, 
macrophage infiltration, and mitigated liver fibrosis (Fig. 8, D to F, 
and fig. S11, B to D). To determine whether the antifibrotic effect of 
4-MU was mediated by inhibiting signaling pathways activated by 
HAS2 or Notch1, we treated Has2DHSC and Notch1DHSC mice with 
4-MU. 4-MU had no further antifibrotic effect beyond Has2 or 
Notch1 deficiency (fig. S11E). Furthermore, we tested the efficacy of 
4-MU on NASH-mediated liver fibrosis. 4-MU efficiently attenuated 
CDHFD-induced collagen deposition (Fig. 8G). These results suggest 
that pharmacological inhibition of HA synthesis could be pursued 
as a therapeutic approach for liver fibrosis.
DISCUSSION
Currently, there are no effective antifibrotic agents for liver fibrosis. 
Many of the known pathways, such as TGF-b, cannot be easily 
targeted because of side effects (24). Our current study establishes that 
HA—to date, only known as a noninvasive serum biomarker for 
liver fibrosis—is actively synthesized in the liver and contributes to 
the development of liver fibrosis. Among the three major HAS 
enzymes, hepatic HAS2 expression correlates well with fibrosis stages 
and serum HA concentrations (Fig. 1). Has2 was markedly up-regulated 
in activated HSCs and in murine and human liver fibrosis. Targeted 
deletion of Has2 in HSCs greatly abrogated HA production and 
reduced liver fibrosis induced by various etiologies, indicating that 
HSCs are the dominant source of HAS2 and HA in the mouse models 
of liver fibrosis that we examined. Hence, liver fibrosis is associated 
with not only increased serum HA due to loss of LSEC-mediated 
HA clearance (12, 13) but also active HA synthesis by HAS2 within 
the liver. We identified that Notch1 is a downstream effector of HA 
and plays a crucial role in HSC activation and liver fibrosis. We also 
demonstrated the interventional potential of targeting HA synthesis 
for the treatment of liver fibrosis. We have provided evidence that, in 
NASH-mediated fibrosis, HAS2 plays a critical role in the progression 
of fibrosis. Because the prevalence of NASH-mediated liver fibrosis 
is increasing and no effective treatment for NASH currently exists, our 
study provides new insight into targeting HAS2 and HA synthesis 
as attractive interventions for NASH-induced fibrosis.
In a physiological condition, circulating and hepatic HA concen-
trations are regulated by the appropriate balance between production 
and clearance. The half-life of plasma HA is 2.5 to 5.5 min, and one-third 
of the total body HA is turned over daily (25, 26). LSECs play a 
prominent role in the elimination of circulating HA in the liver, 
contributing to the rapid clearance and turnover of HA. This could 
be associated with a few or no deposition of HA in the normal liver 
(Figs. 2A and 5B). Tracing of circulating HA labeled by an in vivo 
injection of fluorescently conjugated HA-binding protein using 
intravital microscopy demonstrated that the labeled circulating HA 
was bound to LSECs (27). This finding suggests that LSECs could 
capture and eliminate HA from the circulation.
We previously reported the pathological role of HAS2 overex-
pression and HA production in lung injury and fibrosis in mice and 
patients with idiopathic pulmonary fibrosis (9). In the lung, CD44 
expressed in lung fibroblasts contributes to HAS2-mediated fibrosis 
(9). We recently demonstrated that HA expressed in AEC2s plays a 
role in renewal of these lung progenitor cells (10). In cancer, HA 
participates in cancer stem cell maintenance through CD44. It 
appears that HAS2-generated HA has distinct roles, depending on 
the site of expression, context of disease, and the size of HA (7). 
HMW-HA is protective against injury and inflammation (8). However, 
LMW-HA and HA oligomers are proinflammatory, except for the 
35-kDa HA that has been shown to prevent alcoholic liver disease (28). 
During the progression of liver fibrosis, LMW-HA markedly increases 
 by guest on June 19, 2019
http://stm
.sciencem
ag.org/
Downloaded from
 
Yang et al., Sci. Transl. Med. 11, eaat9284 (2019)     12 June 2019
S C I E N C E  T R A N S L A T I O N A L  M E D I C I N E  |  R E S E A R C H  A R T I C L E
10 of 15
B
Re
l. 
Ha
s2
 m
RN
A
Mo
ck
WT
1
0
1
2
3
A
J
Liver
Re
l. 
Ha
s2
 m
RN
A
Re
l. 
W
t1
 m
RN
A
0
5
10
15
20
25
30
0
3
6
9
12
15
Co
n
K
Re
l. 
HA
S2
 m
RN
A
0
5
10
15
20
Rel. WT1 mRNA
r = 0.7036
P < 0.0001
0 2 4 6 8 10 12
Re
l. W
T1
 m
RN
A
0
0.5
1.0
1.5
2.0
2.5
Re
l. 
W
t1
 m
RN
A
Da
y 1
Da
y 7
C
0
5
10
15
D F
Co
n
Has2 promoter activity
WT1
Mock
pGL3-Has2 (WT)
pGL3-Has2 (mut2)
pGL3-Has2 (mut1)
pGL3-Has2 (mut3)
0 2 4 6 8
##
##
WT1
–636 bp
WT1
–2057 bp Has2
WT1
–1002 bp
AGGGGGGGGCG---GGGCAGGGGCG---CTGCGGGGGGG
AGGGGGGGGCG---GGGCAGGGGCG---CTGCGACGATG
AGGGGGGGGCG---GGGCAACGATG---CTGCGGGGGGG
AGGGGACGATG---GGGCAGGGGCG---CTGCGGGGGGG
–2057 bp –1002 bp –636 bp
##
0
1
2
3
4
– + – +
siCon siWT1
Re
l. 
Ha
s2
 m
RN
A
E
F0/1 (n = 11)
F4 (n = 10)
I
– + – +
siCon siWT1
G Sham
BDL
Corn oil
CCl4
0
50
100
150
200
0
5
10
15
20
25
30
HSC Liver HSC
Re
l. 
W
t1
 m
RN
A
0
0.5
1.0
1.5
2.0
2.5
3.0
Re
l. 
Co
l1
a1
 m
RN
A
– + – +
Cd44–/–
– + – +
WT
#
##
##
H
Re
l. 
Co
l1
a1
 m
RN
A
0
0.5
1.0
1.5
2.0
2.5
F0
 (n
 = 
4)
F1
 (n
 = 
7)
F2
 (n
 = 
27
)
F3
 (n
 = 
17
)
F4
 (n
 = 
10
)
Fig. 7. WT1 transcriptionally regulates HAS2 in HSCs. (A) qRT-PCR assay for Has2 after TGF-b treatment in mouse HSCs (n = 5). (B) Site-directed mutagenesis analysis of 
WT1-binding sites in the Has2 promoter (three replicates in each of five experiments). **P < 0.01 versus pGL3-Has2 (WT) and mock-transfected cells; ##P < 0.01 versus 
pGL3-Has2 (WT) and WT1-transfected cells. (C) Effect of WT1 overexpression on Has2 mRNA expression (n = 3). (D) qRT-PCR assays for Wt1 after TGF-b treatment (n = 5). 
(E and F) Effect of WT1 knockdown on TGF-b–induced Has2 and Col1a1 mRNA (n = 3 to 7). (G) Col1a1 mRNA expression (n = 7 to 8). Mouse HSCs were treated with or 
without TGF-b. (H) Wt1 mRNA expression in quiescent (day 1) or activated (day 7) HSCs (n = 3 per group) and (I) in the liver (sham, n = 10; BDL, n = 12; Con, n = 8; CCl4, 
n = 24) and in vivo–activated HSCs (n = 3 per group). (J) WT1 mRNA expression in patients with fibrosis and chronic hepatitis B. (K) Pearson correlation coefficient analysis of 
WT1 and HAS2. (A to I) Data are means ± SEM and (J) SD. *P < 0.05 and **P < 0.01 versus relative control; #P < 0.05 and ##P < 0.01 versus WT–TGF-b. Two-tailed Student’s t test 
(A, C and D, and H and I) and one-way ANOVA with Tukey’s post hoc analysis (B, E to G, and J).
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in blood and liver tissues and is almost absent in normal conditions. This 
suggests that LMW-HA may be a sensitive biomarker for evaluating 
early liver fibrosis and/or regression of fibrosis after treatment.
Our experiment using Has2DHSC mice determined that HSCs are 
the responsible cells expressing HAS2 for HA production in liver 
fibrosis. We examined the regulatory mechanisms driving HAS2 
expression in HSCs. TGF-b is a robust fibrotic mediator that 
up-regulates Has2 expression in HSCs. We identified WT1-binding 
elements in the HAS2 promoter. In idiopathic pulmonary fibrosis, 
WT1 is overexpressed in mesothelial and mesenchymal cells and 
promotes pulmonary fibroblast activation and ECM production (29), 
further corroborating our data showing that WT1 plays a crucial role 
in TGF-b–mediated HAS2 induction and HSC activation. It is conceiv-
able that WT1 plays a fibrogenic role in general populations of HSCs, 
which may not be limited in mesothelial cell–derived HSCs.
We found that HAS2-produced HA can mediate HSC transdiffer-
entiation to ECM-producing myofibroblasts in an autocrine manner. 
HAS2-generated HA induces production of ECM through CD44 or 
TLR4. HAS2-generated HA also promotes invasive phenotypes of HSCs, 
which corroborates our previous study showing HAS2-mediated 
invasive phenotypes of lung myofibroblasts through CD44 (9). 
Activated myofibroblasts migrate toward the fibrillary matrix by 
acquiring an invasive capacity to destroy the basement membrane in 
fibrotic disease. In liver fibrosis, activated HSCs migrate to inflammatory 
BDL-Veh BDL–4-MU
Sirius
red
HABP
D
Veh
4-MU
Sham BDL
0
50
100
150
200
250
0
5
10
15
Sham BDL
Li
ve
r H
A 
co
nt
en
t
(n
g/
m
g 
w
et
 li
ve
r)
Si
riu
s r
ed
–
po
sit
iv
e 
ar
ea
 (%
)
E F
0
0.2
0.4
0.6
0.8
1.0
1.2
4-MU
Re
l. 
Co
l1
a1
 m
RN
A
– +
0
0.2
0.4
0.6
0.8
1.0
1.2
G
FP
-p
os
iti
ve
 a
re
a
(fo
ld
 c
ha
ng
e)
4-MU– +
Veh
4-MU
Col-GFP CellTracker Overlay
A
B C
G
0
5
10
15
Si
riu
s r
ed
–
po
sit
iv
e 
ar
ea
 (%
)
ND CDHFD
CDHFD-Veh CDHFD–4-MU
Veh
4-MU
Sirius
red
Fig. 8. 4-MU treatment prevents liver fibrosis progression. (A) Representative immunofluorescence staining images. HSCs were isolated from Col-GFP mice. Two days 
after seeding, cells were treated with either vehicle (Veh) or 0.5 mM 4-MU for 6 days. (B) Quantification of GFP-positive area in (A) by ImageJ (n = 3). (C) Col1a1 mRNA 
expression (n = 3). (D) Representative images of HA and Sirius red staining in mouse liver. One week after BDL, mice were orally gavaged with either Veh or 4-MU (450 mg/kg) 
once daily for 2 weeks. (E) Liver HA content after 4-MU treatment (Sham-Veh, n = 4; Sham–4-MU, n = 5; BDL-Veh, n = 11; BDL–4-MU, n = 10). (F) Quantification of Sirius red 
staining in (D) (Sham-Veh, n = 4; Sham–4-MU, n = 5; BDL-Veh, n = 5; BDL–4-MU, n = 10). (G) Sirius red staining in mouse liver. At 11 weeks of CDHFD feeding, mice were 
orally gavaged daily with Veh or 4-MU (450 mg/kg) for 4 weeks (ND, n = 6 per group; CDHFD-Veh, n = 9; CDHFD–4-MU, n = 10). Data are means ± SEM. **P < 0.01. Two-tailed 
Student’s t test (B and C) and one-way ANOVA with Tukey’s post hoc analysis (E to G). Scale bars, 100 mm.
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and fibrotic sites and must navigate the basement membrane and ECM 
in the space of Disse, activities that further perpetuate HSC activation 
and enhance inflammation and fibrosis (30, 31). Previous studies 
suggest that matrix metalloproteinases (MMPs) and integrins a1b1 
and a2b1 mediate the degradation of surrounding ECM and promote 
HSC migration in response to ECM (30, 31).
Notch1 signaling requires sequential proteolytic cleavage of Notch 
receptors to release the Notch-ICD, which translocates to the nucleus 
and binds to RBPj to induce Notch target genes, such as Hes1 and 
Hey1. Patients with Alagille syndrome, who have mutations in 
the NOTCH ligand JAGGED1, display hypoplastic intrahepatic bile 
ducts and slow fibrosis progression with limited ECM deposition, 
suggesting Notch as a driver for liver fibrosis (32). Notch transcripts 
are up-regulated in patients with biliary fibrosis (33), and Notch 
inhibitors suppress TGF-b–induced HSC activation and liver fibrosis 
(18). Jagged-1 and Hes1 induce fibrogenic phenotypes of HSCs (14, 32). 
Hes1 can bind to COL1A1 and COL1A2 promoters and induce these 
genes (34). These findings corroborate our data showing that Notch1 
promotes ECM production in HSCs. Notch1 expression could be 
transcriptionally regulated by HAS2 and CD44. Similar to the Notch1 
receptor, CD44 activation induces CD44 cleavage by metalloproteases 
and g-secretase, releasing the CD44-ICD into the cytoplasm (35). 
CD44-ICD is then translocated into the nucleus and where it regulates 
expression of specific genes, such as MMP-9 (36). Our data show that 
CD44-ICD promotes NOTCH1 transcription. Furthermore, TLR4 
regulation of Notch1 has been reported (37, 38). Conversely, Notch 
signaling can augment or inhibit TLR4-triggered inflammatory 
responses, suggesting that Notch1 regulation of TLR4 activation is 
context dependent (39, 40).
While HMW-HA has tissue protective effects, HMW-HA is 
degraded into LMW-HA in the setting of inflammation (7), which 
alters the homeostatic environment. Thus, the administration of 
HMW-HA may not be an ideal therapy for liver fibrosis. A phase 
3 clinical trial is in progress investigating cancer treatment with 
hyaluronidase(s) to accelerate HA degradation (41). However, this 
strategy could produce intermediate LMW-HA products that accumu-
late because of dysfunctional LSECs in cirrhosis, causing detrimental 
effects. 4-MU can reduce fibroblast HA production by depleting cellular 
uridine diphosphate glucuronic acid (23). The pharmacological 
efficacy of 4-MU was widely tested in cancers (23). 4-MU is a safe 
and well-tolerated agent, and no serious adverse effects were reported 
(23). Our data show that 4-MU treatment inhibited HSC activation, 
suggesting that 4-MU inhibits autocrine production of HA and 
subsequent HSC activation. Moreover, our study revealed that 
inhibiting endogenous HA synthesis by 4-MU reduced liver fibrosis. 
Thus, repurposing 4-MU could be a safe interventional strategy for 
treating liver fibrosis.
There are limitations regarding HA-mediated Notch1 activation in 
our study. We have shown the underlying mechanism of HA-CD44– 
mediated Notch1 up-regulation. However, Notch1 receptor activation 
requires engagement by its ligand, and its exact activation mechanism 
in liver fibrosis remains elusive. HA is known to capture various 
ligands, shuttling them to cell surface receptors (42). The soluble 
form of Jagged-1 may be shuttled by HA to Notch1. Unlike membrane- 
bound Jagged-1, the soluble forms of Jagged-1 generally antagonize 
Notch1 signaling (43). The engagement of Notch1 by the membrane- 
bound Jagged-1 could be crucial for Notch1 activation. Because 
Kupffer cells and HSCs express Jagged-1, it is conceivable that 
HSC-derived HA and chemokines, such as CCL2, promote the 
recruitment of Jagged-1–expressing Kupffer cells and HSCs to 
Notch1-expressing HSCs. Membrane-bound Jagged-1 could then 
bind to Notch1 in HSCs through cell-cell interactions, thereby activating 
Notch1. However, the hypothesis that HA-mediated Jagged-1 and 
Notch1 interact in HSCs needs further investigation. Nevertheless, our 
study provides new insight into the critical role of overexpressed 
HAS2 and HA in mediating HSC activation and liver fibrosis (fig. S11F). 
The profibrogenic role of Notch1 and a relationship between Notch1 
and HAS2 in regulating liver fibrosis were also identified. Our study 
suggests that targeting HAS2 and inhibiting HA production through 
repurposing 4-MU may be an effective strategy to treat or prevent 
liver fibrosis. This strategy is likely to avoid the many known side 
effects associated with TGF-b inhibition (24).
MATERIALS AND METHODS
Study design
This study was designed to determine the role of HAS2-mediated 
HA production in liver fibrosis and to investigate the therapeutic 
potential of HA inhibition. All human sample collection and study 
protocol were approved by Clinical Ethics Committee of Putuo Hospital 
of Shanghai University of Traditional Chinese Medicine, Cedars-Sinai 
Medical Center, California Liver Research Institute, and the Princess 
Alexandra Hospital. For in vivo studies, study protocols were ap-
proved by Cedars-Sinai Medical Center Institutional Animal Care 
and Use Committee. The ARRIVE (Animal Research: Reporting of 
In Vivo Experiments) guideline was followed. Sample size for animal 
studies was based on statistical analysis of variance and on previous 
experience with similar in vivo studies. On the basis of pre-established 
methodology in our laboratory, we rarely exclude values except for 
technical reasons such as inability to obtain enough serum/tissue or 
animals reported to be in distress by Comparative Medicine staff at 
Cedars-Sinai Medical Center. Animals were randomly assigned to 
experimental groups. Experimentalists were not blinded to different 
treatments. However, analysis of samples was performed blindly. 
There was no blinding in cell culture experiments. Most experiments 
were independently replicated three or more times. A sample size 
(n) for each experimental group/condition is indicated in the figure 
legends. Individual subject-level values are reported in data file S1.
Human samples
The study used deidentified liver tissues that were obtained from 65 
patients with chronic HBV infection with clinically diagnosed liver 
fibrosis who underwent liver biopsy from February 2013 to July 2016 in 
the Putuo Hospital, Shanghai University of Traditional Chinese Medicine 
(Shanghai, China). Before biopsy, the patients had not received 
antiviral or other drugs. The stage of liver fibrosis was determined 
by Department of Pathology, Putuo Hospital. Exclusion criteria 
included renal and/or hepatic failure, acute coronary syndromes, 
valvular heart diseases, autoimmune thyroid diseases, or systematic 
inflammatory diseases. The liver biopsy samples of 55 patients with 
chronic hepatitis C were collected between 2000 and 2015 at the 
Princess Alexandra Hospital (Brisbane, Australia). Details of this cohort are 
detailed in (17). Liver biopsy samples and serum samples of patients with 
NAFLD were collected from April 2016 to February 2018 in Cedars-Sinai 
Medical Center (Los Angeles, CA) and California Liver Research Institute 
(Pasadena, CA). Pathologists reviewed the specimens and determined 
the degrees of fat, lobular/portal inflammation, hepatocyte ballooning, 
and fibrosis stage. Controls (F0) were obtained from patients with NAFLD 
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who have found no fibrosis on biopsies. Deidentified samples were 
used. Written informed consent was obtained from all patients.
Mice
Lrat-Cre Tg, Has2fl/fl, ASMA-HAS2 Tg, Collagen a1(I)–GFP Tg, and 
Cd44−/− mice, described previously (21, 44–47), were used at 8 to 
12 weeks of age in C57BL/6 background. Tlr4−/− mice were provided 
by S. Akira (Osaka University, Japan) (48). Notch1fl/fl mice were 
purchased from the Jackson Laboratory. Mice carrying the floxed 
allele of Has2 or Notch1 were crossed with Lrat-Cre Tg mice to generate 
Has2DHSC or Notch1DHSC, respectively. To generate Notch1DHSC/ 
ASMA-HAS2 Tg mice, ASMA-HAS2 Tg mice were crossed with 
Notch1DHSC mice. Collagen a1(I)–GFP Tg mice were crossed with 
ASMA-HAS2 Tg. Mice were back-crossed at least 10 generations onto 
the C57BL/6 background. All studies were performed in accordance 
with National Institutes of Health (NIH) recommendations outlined 
in the Guide for the Care and Use of Laboratory Animals.
Liver fibrosis models
For the BDL model, mice were anesthetized with the injection of keta-
mine and xylazine. After midline laparotomy, the common bile duct was 
ligated twice with 6-0 silk sutures, and the abdomen was closed. Sham 
operation was performed similarly, except that the bile duct was not li-
gated. For DDC model, mice were fed with 0.1% DDC-supplemented 
diet (catalog no. S4643, Bio-Serv) for 4 weeks. For diet-induced NASH 
fibrosis model, mice were fed with CDHFD (60% of calorie from fat; 
catalog no. D05010403, Research Diets) for 12 weeks or CDAA diet (catalog 
no. 518753, Dyets Inc.) for 22 weeks. Rodent standard chow was used 
as a control diet. For the CCl4 model, mice were injected with CCl4 
(0.5 ml CCl4/g mouse body weight, 1:4 dilution with corn oil) (catalog 
no. 319961, Sigma-Aldrich) intraperitoneally every 3 days for a total of 
10 injections. Control mice received corn oil. For TAA model, TAA 
(catalog no. 163678, Sigma-Aldrich) was administered at a dose of 
300 mg/liter in drinking water for 20 weeks.
Histologic examination
For a-SMA staining in mouse liver tissues, mouse anti–a-SMA 
monoclonal antibody (1:200; catalog no. M0851, Dako) and the 
M.O.M. Kit (catalog no. MKB-2225, Vector Laboratories) were applied 
according to the manufacturer’s instruction. For F4/80 staining, 
monoclonal antibody to F4/80 (clone BM8; catalog no. 14-4801, 
eBioscience) was applied. To detect HA in livers of DDC diet–fed 
mice (fig. S4A), Avidin, AP conjugate (catalog no. 434422, Invitrogen), 
and ImmPACT Vector Red Alkaline Phosphatase substrate (catalog 
no. SK-5105, Vector Laboratories) were used to distinguish HA 
from endogenous bile. Neutral lipids were analyzed by Oil Red 
O staining. Oil Red O–positive area was evaluated from randomly 
selected 10 fields of ×200 magnification per slide by ImageJ. HA 
staining was performed as previously described (8). After routine 
deparaffinization, hydration, and blockage of endogenous peroxidase, 
tissues were incubated with biotin-labeled HA-binding protein (4 mg/ml) 
[rhAggrecan aa20-675/His (NSO/7), biotin, R&D Systems] for 2.5 hours 
and then incubated and developed using a VECTASTAIN Elite ABC 
kit and DAB Peroxidase Substrate kit (catalog nos. PK-6100 and 
SK-4100, Vector Laboratories).
HA ELISA and HA fragmentation
We measured amounts of HA in the serum or the liver homogenates 
or the culture supernatants with the commercial Hyaluronan 
DuoSet ELISA Kit (catalog no. DY3614, R&D Systems). Samples were 
run in duplicate. A size-specific HA fraction in human serum and 
mouse liver homogenates was determined as previously described 
(47), with modification. Liver homogenates were digested with Pronase 
at 60°C for 4 hours and then boiled for 30 min. The samples were 
fractionated on 100- and 300-kDa molecular weight cutoff columns 
(catalog nos. 13269-E and 13279-E, Centrisart, Sartorius). The 
filtered HA with molecular weights less than 100 kDa or less than 
300 kDa were collected, and the amount of HA in the unfiltered 
and filtered serum or liver homogenate samples was quantified 
by the Hyaluronan DuoSet ELISA Kit.
RNA-seq sample preparation and sequencing
Total RNA was extracted from primary HSCs using TRIzol and 
purified using the NucleoSpin RNA Kit, according to the manufacturer’s 
instructions. RNA purity, concentration, and integrity were evaluated 
with an Agilent 2100 BioAnalyzer (Agilent Technologies). Beijing 
Genomic Institute performed the RNA-seq. RNA libraries were 
prepared for sequencing via an Illumina HiSeq 4000 using standard 
BGISEQ-500 protocols.
RNA-seq data analysis
TopHat2 (version 2.0.12) was applied to align sequencing reads to 
the reference mouse genome (GRCm38/mm10). The relative gene 
expression RPKM and read counts were estimated using SAMMate 
(version 2.7.4) and HTSeq (version 0.6.1) with Ensembl database 
(Mus Musculus.GRCm38.82). DESeq2 was applied to conduct dif-
ferential gene expression analysis using read counts. The P values of 
multiple tests were adjusted using Benjamini-Hochberg’s method, 
and the significance level was designated as false discovery rate 
(FDR) < 0.01 and |log2 FC| > = 1. Pathway and Gene Ontology term 
enrichment analysis of differentially expressed genes was performed 
using DAVID. For analysis of HAS1, HAS2, and HAS3 expression 
in the hepatitis C virus (HCV) patient cohort, normalized RNA-seq 
read counts (counts per million) on unfiltered data were analyzed 
and presented as previously described (17).
Quantitative real-time polymerase chain reaction
Total RNA from snap-frozen liver tissues were extracted using the 
NucleoSpin RNA kit (catalog no. 740955.50, Macherey-Nagel), and 
the total RNA from cells were extracted using TRIzol RNA isolation 
reagents (catalog no. 15596-018, Invitrogen). It was reverse-transcribed 
to complementary DNA (cDNA) with the PrimeScript RT Reagent 
Kit (catalog no. RR037A, Takara) or High-Capacity cDNA Reverse 
Transcription Kit (catalog no. 4368814, Applied Biosystems). qPCR 
was performed using SYBR Green (catalog no. RR420A, Takara) or 
iTaq Univer SYBR Green Supermix 1000 (catalog no. 1725122, Bio-Rad) 
by ABI ViiA 7Dx real-time PCR system (Applied Biosystems) or 
CFX96 real-time PCR system (Bio-Rad). The qPCR primer sequences 
used in this study are listed in table S1. 18S ribosomal RNA was used 
as an internal control for the normalization.
In vitro treatment
The HSCs were isolated and cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS) for 3 days. 
The cells were deprived of serum overnight and subsequently exposed 
to LMW-HA (100 mg/ml; 135 kDa) in the presence of polymyxin B 
(10 mg/ml; catalog no. 5291, Sigma-Aldrich) (8), HMW-HA (600 mg/ml; 
Healon, Kabi Pharmacia Ophthalmics Inc.), LPS (100 ng/ml; catalog 
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no. L9764, Sigma-Aldrich), or TGF-b (5 ng/ml; catalog no. 580704, 
BioLegend) for 12 hours. Kupffer cells were maintained in RPMI 
medium with 10% FBS for 6 hours and then serum deprived for 
overnight. The next day, cells were treated with LMW-HA (100 mg/ml) 
in the presence of polymyxin B (10 mg/ml) or HMW-HA (600 mg/ml) for 
4 hours. To deplete Notch1 in HSCs, cells were isolated from Notch1fl/fl 
mice and cultured in DMEM with 10% FBS for 2 days and then infected 
with recombinant adenovirus (Ad) expressing GFP or Cre recombinase. 
Cells were collected at day 10. The infection efficiency was confirmed 
by GFP visualization, and the efficiency of Notch1 deletion by Ad-Cre 
transduction was monitored by qPCR.
Promoter luciferase assay
The HEK293A cells were maintained in DMEM containing 10% FBS, 
penicillin (50 U/ml), and streptomycin (50 mg/ml) at 37°C in a humid-
ified atmosphere with 5% CO2. The human NOTCH1 promoter 
(−1239/+1) and customized human NOTCH1 promoter (−1239/+1684) 
vectors were purchased from GeneCopoeia (catalog no. HPRM48887-
PG04). The NOTCH1 promoter luciferase mutant exhibiting point 
mutations in the CIRE2 at position +1517 (WT: CCTGCG; mut: 
AAGTAT) from NOTCH1 promoter (−1239/+1684) vector was 
generated by GENEWIZ Inc. The 2880–base pair (bp) Has2 promoter 
luciferase reporter plasmid was provided by C. Chiang (Vanderbilt 
University Medical Center) (49). Three different Has2 promoter 
luciferase mutants exhibiting point mutations in the WT1-binding 
motifs at positions −2057 bp (WT: AGGGGGGGGCG; mut1: 
AGGGGacGatG), −1002 bp (WT: GGGCAGGGGCG; mut2: GGG-
CAacGatG), and −636 bp (WT: CTGCGGGGGGG; mut3: CTGC-
GacGatG) from the transcription start site (TSS) were generated from the 
original 2880-bp Has2 promoter reporter. We performed mutagen-
esis of pGL3-Has2 starting construct via 5′ Pvull and 3′ BspHI to generate 
pGL3-Has2-mut1 or pGL3-Has2-mut2 vectors, with sequence verifica-
tion across the region of interest (1373 bp). Mutagenesis starting con-
struct via 5′ BspHI and 3′ Spel was done to generate pGL3-Has2-mut3, 
with sequence verification (160 bp) by sequencing (GENEWIZ Inc.). 
Luciferase assays were performed using the Secrete- Pair Dual Lumi-
nescence Assay Kit (catalog no. LF032, GeneCopoeia) or Dual- Glo 
Luciferase Assay System (catalog no. E2920, Promega), in accordance with 
the manufacturers’ instruction. HEK293 cells were cotransfected with 
promoter constructs and CD44- or WT1-expressing plasmid (catalog 
no. MR225851, Origene) for 24 to 48 hours before the luciferase assay.
4-MU in vivo treatment
4-MU or vehicle control (2% sucrose) was given via oral gavage of 
450 mg/kg once daily. WT or Has2DHSC or Notch1DHSC mice were 
treated with 4-MU or vehicle control starting from days 7 to 21 after 
BDL. In a separate set of experiments, after 11 weeks of CDHFD 
feeding, C57BL/6 mice were orally gavaged daily with vehicle or 
4-MU for 4 weeks under continuous feeding of CDHFD.
Statistical analysis
Statistical significance was assessed by using GraphPad Prism 5.01 
software (GraphPad Software Inc). Differences between the two 
groups were compared using a two-tailed unpaired Student’s t test. 
Differences between multiple groups were compared using one-way 
ANOVA, followed by Tukey’s post hoc analysis. Multiple linear 
regression analysis was performed to find the correlation of hepatic 
HAS2 expression with serum HA contents or genes of interests. 
P values of <0.05 were considered significant.
SUPPLEMENTARY MATERIALS
stm.sciencemag.org/cgi/content/full/11/496/eaat9284/DC1
Materials and Methods
Fig. S1. Expression of HAS in patients with fibrosis.
Fig. S2. Expression of HA and Has expression in mouse liver cells.
Fig. S3. Increased susceptibility to BDL- or CCl4-induced liver fibrosis in ASMA-HAS2 Tg mice.
Fig. S4. Generation of HSC-specific Has2 knockout mice.
Fig. S5. Effect of HSC-specific Has2 deficiency on DDC-induced liver fibrosis.
Fig. S6. No effect of HSC-specific Has2 deletion on CDHFD-mediated fat accumulation or 
glucose intolerance.
Fig. S7. Cd44 and Tlr4 mRNA expression in in vivo–activated HSCs.
Fig. S8. HA concentration in the supernatant of WT HSCs or HAS2 Tg HSCs.
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